Compound index

Tissue Repair & Cytoprotective Research Peptides

Thymosin beta-4

Also known as Tβ4

Late-stage human trialsInvestigational

Last reviewed: 2026-11-19

Evidence status & limitations

Human studies test defined thymosin beta-4 products and endpoints; their results cannot be transferred to an unidentified fragment or material.

Regulatory status

No FDA-approved human medicine for this exact identity was established in this review. Investigational research is not approval.

    Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.

    WADA prohibited status: current list and context

    Known risks & open questions

    Long-term systemic safety and clinical efficacy remain incompletely established.

    Key sources

    Identity and editorial screen completed November 19, 2026. Previously checked primary references retained; this is not an exhaustive clinical review.

    Related compounds

    • BPC-157

      Same scientific class · A 15-amino-acid chain. · Early human trials

    • Thymosin beta-4 fragment (17–23)

      Same scientific class · A seven-amino-acid sequence, LKKTETQ, corresponding to residues 17–23 of thymosin beta-4. · Cell/lab studies only

    Related glossary terms